Regression of Fatty Heart by Valsartan Therapy

• Status: Withdrawn
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Traditionally, obesity is considered an indirect cause of heart disease. Obese individuals typically present with a number of traditional Framingham risk factors (hypertension, dyslipidemia, and type 2 diabetes), predisposing them to heart attacks and subsequent heart failure. However, an emerging body of basic research revisits a hypothesis that fat is a direct cardiotoxin. Under healthy conditions, most triglyceride is stored in fatty tissue (adipocytes) while the amount of triglyceride stored in non-adipocyte tissues (such as the pancreas, the liver, skeletal muscle, and heart) is minimal and very tightly regulated. When this regulation is disrupted, intracellular triglyceride accumulates excessively in these organs ("steatosis") and has been implicated in activating adverse pathways which culminate in irreversible cell death ("lipotoxicity"), leading to several well-recognized clinical syndromes. These include non-alcoholic steatohepatitis (NASH), pancreatic beta-cell failure in type 2 diabetes, and dilated cardiomyopathy.

It has been recently observed that angiotensin II receptor blockers (ARBs) in addition to lowering blood pressure improve insulin sensitivity and decrease the risk for type 2 diabetes. This study will test the above theory in two study groups: Valsartan vs. Hydrochlorothiazide. We hypothesize that in obese humans with elevated myocardial triglycerides, blockade of the renin-angiotensin system (Valsartan group) will reduce myocardial fat with improvement of insulin sensitivity and heart function.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Collaborator: Novartis Pharmaceuticals
• Treatments: Hydrochlorothiazide; Valsartan

Criteria

Inclusion Criteria:

• Prediabetic individuals with impaired glucose tolerance (2 hr postprandial glucose > 140mg/dL) or having 3 of 5 Metabolic Syndrome criteria:

1. Fasting glucose > 100mg/dL;

2. Waist circumference: men > 102cm, women > 88cm (confirmed with abdominal MRI);

3. HDL: men < 40mg/dL, women < 50mg/dL;

4. Triglycerides > 150mg/dL;

5. Blood pressure > 130/80mmHg;

• Elevated hepatic triglycerides (>5.5%) and myocardial triglycerides (>0.6%)

• Elevated blood triglycerides >150mg/dL

• Age < 50 years

Exclusion Criteria:

• Type 2 Diabetes mellitus

• Prior exposure to renin system blockers or HCTZ

• BP > 160/100mmHg

• Claustrophobia

• Metallic implants in body

• Pregnant or planning to become pregnant

• Prior exposure to statin medications